Cytokinetics, Incorporated Common Stock Earnings Dividend

Cytokinetics, Incorporated Common Stock’s revenue fell -52.2% since last year same period to $31.91Mn in the Q2 2026. On a quarterly growth basis, Cytokinetics, Incorporated Common Stock has generated 64.89% jump in its revenue since last 3-months.

Cytokinetics, Incorporated Common Stock’s net profit fell -47.92% since last year same period to $-198.76Mn in the Q2 2026. On a quarterly growth basis, Cytokinetics, Incorporated Common Stock has generated 3.53% jump in its net profits since last 3-months.

Cytokinetics, Incorporated Common Stock’s net profit margin fell -209.47% since last year same period to -622.81% in the Q2 2026. On a quarterly growth basis, Cytokinetics, Incorporated Common Stock has generated 41.49% jump in its net profit margins since last 3-months.

Cytokinetics, Incorporated Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.63 - a 1.21% jump from last quarter’s estimates.

Cytokinetics, Incorporated Common Stock’s earning per share (EPS) estimates for the current year stand at -1.63.

Cytokinetics, Incorporated Common Stock’s earning per share (EPS) fell -33.93% since last year same period to -1.5 in the Q2 2026. This indicates that the Cytokinetics, Incorporated Common Stock has generated -33.93% annual rate of fall in its earning per share (EPS) in the last 4 quarters.